2FIRSTS | As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary argues real-world evidence complements clinical trials for regulating nicotine products, coinciding with FDA's JUUL2 authorization.Summary
A commentary published in the Harm Reduction Journal argues that randomized controlled trials (RCTs) are essential for determining efficacy under controlled conditions, but real-world evidence (RWE) is crucial for assessing real-world effectiveness, consumer uptake, and population-level impact. The authors propose a framework where 'Impact = Reach × Efficacy,' emphasizing that strong clinical efficacy may have limited population impact if product uptake is low. The article advocates for greater use of longitudinal, actual-use, and market evidence for fast-evolving categories like e-cigarettes, heated tobacco, and nicotine pouches. It acknowledges significant methodological limitations of RWE, such as confounding and selection bias, and argues it should complement rather than replace RCTs. The commentary notes its authors have ties to JUUL Labs. Its publication coincided with the U.S. FDA's marketing authorization for JUUL2 devices, which highlighted data on adult smokers completely switching to the product, underscoring the regulatory importance of complete switching and population-level risk-benefit assessment.
(Source：2Firsts)
